Africa’s pharmaceutical landscape sits at a structural crossroads. Despite a healthcare market valued at over $50 billion annually, the continent still imports over 70% of its medicines, leaving supply chains exposed to global shocks, currency pressures, and geopolitical disruptions.

The COVID-19 pandemic intensified this vulnerability, exposing how quickly vaccine nationalism and export restrictions can disrupt access to essential drugs. In response, a new class of industrial leaders is reshaping Africa’s drug sovereignty agenda.

These are not only wealthy entrepreneurs, but also founders and executives controlling manufacturing capacity, distribution networks, and increasingly, research-driven pharmaceutical ecosystems.

From North Africa’s export-oriented producers to Southern Africa’s large-scale generics manufacturers, and West Africa’s fast-growing indigenous pharma firms, these moguls are redefining what local production means in practice.

Their influence extends beyond profit margins. Collectively, they are expanding access to antimalarials, antibiotics, insulin, and vaccines while reducing dependency on imports. Strategic partnerships with global pharmaceutical firms, technology transfer agreements, and investments in biologics are accelerating Africa’s transition from consumer to producer.

This list highlights 10 key pharmaceutical power players across the continent whose companies are shaping manufacturing depth, healthcare access, and the long-term vision of pharmaceutical self-sufficiency under the African Continental Free Trade Area (AfCFTA).

Shore Africa has profiled 10 pharmaceutical moguls whose companies, capital, and vision are shaping the future of medicine in Africa.

1. Patrick Soon-Shiong
Nationality: South Africa
Net Worth: $8.6 billion
Patrick Soon-Shiong is a South African-American transplant surgeon, billionaire businessman, and medical researcher recognized as a pioneer in oncology and immunotherapy. He is the inventor of the cancer drug Abraxane, founder of NantWorks, and Executive Chairman of ImmunityBio, focused on developing therapies for cancer and infectious diseases. His fortune comes from strategic private investments and the sale of two pharmaceutical companies, APP Pharmaceuticals for $4.6 billion in 2008 and Abraxis BioScience for $2.8 billion in 2010. He developed Abraxane, a groundbreaking chemotherapy drug. He holds an 80% stake in ImmunityBio, valued at $1.82 billion, and owns the Los Angeles Times. Soon-Shiong continues to shape the healthcare industry through NantWorks LLC, a conglomerate managing public and private entities worth over $2 billion across Europe and Africa.

2. Stephen Saad
Nationality: South Africa
Net Worth: $1.2 billion
Stephen Saad is a prominent South African billionaire businessman, best known as the co-founder and Group Chief Executive of Aspen Pharmacare, the largest manufacturer of generic medicines in Africa. Founded in 1997, he has built the company into a multinational pharmaceutical giant with a significant global footprint. He also oversees Aspen API, a leading supplier of active pharmaceutical ingredients. Saad is known for his philanthropy through The Stephen Saad Foundation, which provides HIV/AIDS treatment and supports education and healthcare initiatives. He is also the chairman of The Sharks, a top South African rugby team.

3. Ivan & Lynette Saltzman
Nationality: South African
Ivan Saltzman co-founded Dis-Chem Pharmacies in 1978 with his wife, Lynette. Today, Dis-Chem has over 300 retail stores and employs more than 20,000 professionals. Saltzman holds more than 30% ownership stake, making him one of South Africa’s premier investors. Dis-Chem’s extensive network includes linked dispensaries, family clinics, wound care centers, and self-medication hubs, reinforcing its strong presence in the South African healthcare market. The company has a market capitalization of R31.1 billion ($1.95 billion), cementing Lynette Saltzman’s influence in the pharmaceutical industry.

4. Gus Attridge
Nationality: South African
Net Worth: $410 million
Gus Attridge co-founded Aspen Pharmacare, helping transform it into the world’s fifth-largest generic drugmaker. Aspen, valued at R64.9 billion ($3.92 billion), operates 26 manufacturing facilities across six continents. Attridge holds over a 4% stake in Aspen. His leadership in Aspen Manufacturing and investments in Fine Chemicals Corporation and Aspen API have positioned him as a key player in Africa’s pharmaceutical landscape.

Gus Attridge co-founded Aspen Pharmacare alongside Stephen Saad

5. The Tazi family
Nationality: Moroccan
Net Worth: $140 million
The Tazi family is one of Morocco’s most influential business dynasties, founded Société de Thérapéutique Marocaine SA (Sothema) in 1976 and listed in 2005. Sothema has grown into one of Morocco’s leading pharmaceutical manufacturers, producing about 60 million units annually. The company partners with more than 35 multinational laboratories and exports to Europe, the Maghreb, Sub-Saharan Africa, and the Gulf.
The family’s holdings are distributed among second-generation heirs of company founder Omar Tazi, reflecting a tightly held but diversified control structure. The largest individual shareholder is Mohamed Tazi (17.59%), followed by Najia Tazi (9.81%), Lamia Tazi (8.19%), who also serves as chairperson and chief executive officer, Salma Tazi (6.94%), Badiaa Tazi (4%), and Ali Tazi (0.02%).
Their combined stake of 46.55% in Sothema, equivalent to more than 3.35 million shares, is currently worth $142 million.

6. Abdelmadjid Kerrar
Nationality: Algerian
Abdelmadjid Kerrar founded Biopharm in 1992, transforming it from a medicine distributor into one of Algeria’s largest pharmaceutical manufacturers. Biopharm now produces over 200 high-quality products and has diversified into Biopharm Distribution, Algérie Pharma, Biocare Laboratories, and the Kerrar Group. Kerrar’s shift to local production significantly reduced Algeria’s dependence on imports and boosted economic growth.

7. Stellar Okoli
Nationality: Nigerian
Stella Okoli founded Emzor Pharmaceuticals, a leading African manufacturer and distributor of medicines and medical supplies. Emzor produces over 140 pharmaceutical products, including analgesics, vitamins, antibiotics, antimalarials, and cardiovascular drugs. The company has grown into a multimillion-dollar enterprise, cementing Okoli’s legacy in Africa’s pharmaceutical industry.

8. Fidelis Ayebae and family
Nationality: Nigerian
Net Worth: N97.38 billion ($71.5 million)
Fidelis Ayebae founded Fidson Healthcare Plc in 1995, initially as a distributor of pharmaceutical products. By 2002, he established a manufacturing facility, and in 2005, Fidson became the first company in sub-Saharan Africa to produce antiretroviral (ARV) drugs. Today, Fidson operates four manufacturing facilities in Nigeria and is listed on the Nigerian Exchange. Ayebae and his family remain the company’s controlling shareholders, driving its continued growth in Africa’s pharmaceutical market. Together, the family’s 39.4% stake, equivalent to 945.38 million shares, is worth N97.38 billion ($71.5 million).

9. Kofi Nsiah-Poku
Nationality: Ghanaian
Kofi Nsiah-Poku is the founder and CEO of Kinapharma, a leading Ghanaian pharmaceutical company. Established in 1998, Kinapharma manufactures over 150 drugs, including generics and branded products. Nsiah-Poku also founded M&G Pharmaceuticals, further strengthening West Africa’s pharmaceutical sector. His efforts have made medicine more accessible and affordable in the region.

10. Emmanuel Katongole
Nationality: Ugandan
In 1997, Emmanuel Katongole co-founded Quality Chemicals Limited to import generic veterinary and human pharmaceuticals from India. The company formed a joint venture with Cipla of India in 2004 to establish a pharmaceutical factory in Uganda, which was known as Quality Chemical Industries Limited. In November 2013, Cipla took a majority interest in QCIL, renaming Cipla Quality Chemical Industries Limited (CiplaQCIL). The company produces drugs to treat malaria, HIV, and Hepatitis B. In addition, the company is exploring medicine production to help fight non-communicable diseases and cancer.